Literature DB >> 21677258

Oseltamivir and risk of lower respiratory tract complications in patients with flu symptoms: a meta-analysis of eleven randomized clinical trials.

Miguel A Hernán1, Marc Lipsitch.   

Abstract

An independent reanalysis of 11 randomized clinical trials shows that oseltamivir treatment reduces the risk of lower respiratory tract complications requiring antibiotic treatment by 28% overall (95% confidence interval [CI], 11%-42%) and by 37% among patients with confirmed influenza infections (95% CI, 18%-52%).

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21677258      PMCID： PMC3137795          DOI： 10.1093/cid/cir400

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  12 in total

1.  ACP Journal Club. Review: Neuraminidase inhibitors relieve influenza symptoms and reduce laboratory-confirmed influenza in healthy adults.

Authors:  Marek Smieja
Journal:  Ann Intern Med       Date:  2010-02-16       Impact factor: 25.391

2.  Neuraminidase inhibitors--the story behind the Cochrane review.

Authors:  Peter Doshi
Journal:  BMJ       Date:  2009-12-08

3.  Why don't we have all the evidence on oseltamivir?

Authors:  Fiona Godlee; Mike Clarke
Journal:  BMJ       Date:  2009-12-08

4.  Complications: tracking down the data on oseltamivir.

Authors:  Deborah Cohen
Journal:  BMJ       Date:  2009-12-08

5.  [Clinical efficacy and safety of the selective oral neuraminidase inhibitor oseltamivir in treating acute influenza--placebo-controlled double-blind multicenter phase III trial].

Authors:  S Kashiwagi; S Kudoh; A Watanabe; I Yoshimura
Journal:  Kansenshogaku Zasshi       Date:  2000-12

6.  Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group.

Authors:  J J Treanor; F G Hayden; P S Vrooman; R Barbarash; R Bettis; D Riff; S Singh; N Kinnersley; P Ward; R G Mills
Journal:  JAMA       Date:  2000-02-23       Impact factor: 56.272

7.  Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group.

Authors:  K G Nicholson; F Y Aoki; A D Osterhaus; S Trottier; O Carewicz; C H Mercier; A Rode; N Kinnersley; P Ward
Journal:  Lancet       Date:  2000-05-27       Impact factor: 79.321

8.  Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations.

Authors:  Laurent Kaiser; Cynthia Wat; Tracy Mills; Paul Mahoney; Penelope Ward; Frederick Hayden
Journal:  Arch Intern Med       Date:  2003-07-28

Review 9.  Safety and pharmacology of oseltamivir in clinical use.

Authors:  Regina Dutkowski; Bharat Thakrar; Enrico Froehlich; Pia Suter; Charles Oo; Penny Ward
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

10.  Influenza will not miss opportunities.

Authors:  Laurent Kaiser
Journal:  Clin Infect Dis       Date:  2006-11-08       Impact factor: 9.079
View more
  34 in total

1.  Estimating the United States demand for influenza antivirals and the effect on severe influenza disease during a potential pandemic.

Authors:  Justin J O'Hagan; Karen K Wong; Angela P Campbell; Anita Patel; David L Swerdlow; Alicia M Fry; Lisa M Koonin; Martin I Meltzer
Journal:  Clin Infect Dis       Date:  2015-05-01       Impact factor: 9.079

2.  Oseltamivir effect on antibiotic-treated lower respiratory tract complications in virologically positive randomized trial participants.

Authors:  Marc Lipsitch; Miguel A Hernán
Journal:  Clin Infect Dis       Date:  2013-07-24       Impact factor: 9.079

Review 3.  Antiviral Medications in Seasonal and Pandemic Influenza.

Authors:  Regine Lehnert; Mathias Pletz; Annicka Reuss; Tom Schaberg
Journal:  Dtsch Arztebl Int       Date:  2016-11-25       Impact factor: 5.594

4.  Use of influenza antiviral medications among outpatients at high risk for influenza-associated complications during the 2013-2014 influenza season.

Authors:  Fiona Havers; Brendan Flannery; Jessie R Clippard; Manjusha Gaglani; Richard K Zimmerman; Lisa A Jackson; Joshua G Petrie; Huong Q McLean; Mary Patricia Nowalk; Michael L Jackson; Arnold S Monto; Edward A Belongia; Heather F Eng; Lois Lamerato; Angela P Campbell; Alicia M Fry
Journal:  Clin Infect Dis       Date:  2015-02-25       Impact factor: 9.079

5.  Influenza Outbreaks Among Passengers and Crew on Two Cruise Ships: A Recent Account of Preparedness and Response to an Ever-Present Challenge.

Authors:  Alexander J Millman; Krista Kornylo Duong; Kathryn Lafond; Nicole M Green; Susan A Lippold; Michael A Jhung
Journal:  J Travel Med       Date:  2015-06-02       Impact factor: 8.490

6.  Statins and outcomes of hospitalized patients with laboratory-confirmed 2017-2018 influenza.

Authors:  Alaa Atamna; Tanya Babitch; Mayaan Bracha; Nadav Sorek; Ben-Zvi Haim; Avishay Elis; Jihad Bishara; Tomer Avni
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-08-28       Impact factor: 3.267

7.  Oseltamivir pharmacokinetics, dosing, and resistance among children aged <2 years with influenza.

Authors:  David W Kimberlin; Edward P Acosta; Mark N Prichard; Pablo J Sánchez; Krow Ampofo; David Lang; Negar Ashouri; John A Vanchiere; Mark J Abzug; Nazha Abughali; Mary T Caserta; Janet A Englund; Sunil K Sood; Michael G Spigarelli; John S Bradley; Judy Lew; Marian G Michaels; Wen Wan; Gretchen Cloud; Penelope Jester; Fred D Lakeman; Richard J Whitley
Journal:  J Infect Dis       Date:  2012-12-10       Impact factor: 5.226

8.  Association of Oseltamivir Treatment With Virus Shedding, Illness, and Household Transmission of Influenza Viruses.

Authors:  Doug H Cheung; Tim K Tsang; Vicky J Fang; Jiajing Xu; Kwok-Hung Chan; Dennis K M Ip; Joseph Sriyal Malik Peiris; Gabriel M Leung; Benjamin J Cowling
Journal:  J Infect Dis       Date:  2015-02-02       Impact factor: 5.226

9.  Use of influenza antiviral agents by ambulatory care clinicians during the 2012-2013 influenza season.

Authors:  Fiona Havers; Swathi Thaker; Jessie R Clippard; Michael Jackson; Huong Q McLean; Manjusha Gaglani; Arnold S Monto; Richard K Zimmerman; Lisa Jackson; Josh G Petrie; Mary Patricia Nowalk; Krissy K Moehling; Brendan Flannery; Mark G Thompson; Alicia M Fry
Journal:  Clin Infect Dis       Date:  2014-07-16       Impact factor: 9.079

10.  Influenza promotes pneumococcal growth during coinfection by providing host sialylated substrates as a nutrient source.

Authors:  Steven J Siegel; Aoife M Roche; Jeffrey N Weiser
Journal:  Cell Host Microbe       Date:  2014-07-09       Impact factor: 21.023
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.